Better Health for All

Novavax's core mission is to discover, develop, and commercialize innovative vaccines to prevent serious infectious diseases, including COVID-19, combined COVID-19 and influenza, and its adjuvant is used in a malaria vaccine.

This indicates that 100% of its product portfolio delivers revolutionary health benefits, with no revenue from products with negative health outcomes. The company's vaccine candidate is approved for use in persons over 65 or those aged 12-64 with underlying conditions. Novavax participates in the COVAX Facility, supplying 92 lower-income economies with donor-funded doses and partnering with Gavi, which has helped immunize over 1 billion children and prevented more than 17.3 million deaths, demonstrating a revolutionary reach to vulnerable populations. The company has a Clinical Research Policy emphasizing transparency and accountability, and aims to ensure the quality and integrity of data, indicating excellent data practices. Novavax's focus on vaccines for infectious diseases demonstrates a revolutionary emphasis on disease prevention. During the COVID-19 pandemic, Novavax agreed to supply 350 million doses of its vaccine candidate to COVAX, with deliveries commencing in Q3 2021, showing leadership in global health crisis response. However, Novavax's agreement with Gavi includes annual deferred payments of $80 million through 2028, which can be offset by vaccine credits for sales to low-income countries, suggesting a pricing model that is not at cost or below cost for these regions. The company's Clinical Research Policy aims to ensure adherence to ethical standards in clinical research, indicating excellent ethical frameworks.

Fair Pay & Worker Respect

For the 2024 fiscal year, Novavax reported a CEO to median employee pay ratio of 32:1, with the CEO's total compensation at $5,087,461 and the median employee pay at $161,162.

The company also has an Indeed Work Wellbeing Score of 70. Novavax's Code of Business Conduct, revised in September 2021, applies globally to all subsidiaries and business entities, as well as certain business partners. The Code prohibits working with partners who employ child or forced labor, and outlines policies against discrimination and harassment. Employees are encouraged to report concerns anonymously through a corporate compliance hotline, and retaliation is strictly prohibited.

Fair Trade & Ethical Sourcing

Novavax has not received any reports from employees, the public, or law enforcement agencies indicating that modern slavery practices have been identified in its operations or supply chain to date.

The company publishes an annual statement in compliance with the UK Modern Slavery Act of 2015. Novavax conducts due diligence screening of vendors and periodic reviews of suppliers. It has a Code of Business Conduct (NovaCode) and expects business partners to adhere to ethical and legal standards. The company invests in training for employees and management on mitigating risks of human trafficking, slavery, and illegal child labor. Novavax also provides mechanisms for reporting issues, including a confidential whistleblower procedure and a 24-hour helpline.

Honest & Fair Business

Novavax provides a confidential method on its website for submitting concerns regarding accounting, internal accounting controls, or auditing matters, but there is no evidence of independent investigation processes.

The company has a Code of Business Conduct and Ethics applicable to all directors and employees, which meets criteria for a 'Code of Ethics' under applicable regulations, but information on training frequency and effectiveness metrics is not provided.

Kind to Animals

Novavax is listed by Cruelty Free Investing for exploiting animals, indicating that not a single product is certified cruelty-free.

The company conducts animal testing for its medical products, research, and therapies, including preclinical trials on animals, as stated in a press release. Novavax has tested vaccines on ferrets for H1N1 and used rabbits in safety studies. The company uses between 50,000 and 100,000 animals annually, with no transparent reduction targets mentioned. Less than 1% of Novavax's R&D budget is allocated to animal-free technologies, as evidenced by the company's use of animal testing for vaccine development and lack of specific investment figures for alternatives.

No War, No Weapons

The provided articles focus on Novavax's vaccine research, development, partnerships, and FDA approvals.

Neither article contains any specific, concrete data points or information relevant to the 'No War, No Weapons' ethical value, such as revenue from arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other related KPIs. Therefore, no KPIs can be scored based on the evidence provided.

Safe & Smart Tech

Novavax has not reported any documented data breaches, despite being targeted by hackers, and states that its data integrity was not compromised.

The company has also not reported any incidents of unauthorized data use, with evidence suggesting preventative measures are in place. Novavax's privacy policy outlines standard user data rights, including access, rectification, erasure, and the right to opt-out of selling or sharing data for targeted advertising. The company uses Recorded Future to monitor for vulnerabilities across its vendors and suppliers, which has reduced daily alerts from thousands to about ten, indicating good vulnerability management. Novavax retains personal data for legitimate business purposes, with criteria including legal obligations and dispute resolution, and stores aggregated and anonymized data indefinitely if users stop using services, which indicates limited data minimization practices. The company provides disclosure reports for multiple countries and years (2022-2024) and states that Recorded Future helps meet some compliance controls. There is no evidence of a bug bounty program.